Replies to post #115623 on Amarin Corp Plc (AMRN)

[Biobillionair]

Rose-The mineral oil was raised as a false flag and excuse to rescind ANCHOR without any considerations to R-I and the damages the slanderous allegation would have on the future stock action of AMRN. As you can see, the damages are real the stock doesn't trade normally: the value of R-I is not priced into the stock because the FDA has already cried foul with R-I placebo. There's no undoing this except R-I approval and label.
BB

[HDGabor]

r-

the inertness of the mineral oil placebo ... If that was a concern

The FDA tried to explain the changes observed in the mineral oil group, since the magnitude of the changes in several lipid and lipoprotein parameters, as well as biomarkers of inflammation, between baseline and Week 12 in the placebo group wre rather atypical for lipid-lowering trials. However they did not conclude anything

These results suggest the changes in ANCHOR are atypical, but the etiology of this remains unclear

and did not suggest any change for R-IT.

Furthermore, R-IT is about clinical outcome (as PE and SEs) lipid values are TEs only (meanwhile ANCHOR was about lipids).

Best,
G